Abstrakt
BackgroundPeople over age 50-55 have historically been excluded from randomized clinical trials for multiple sclerosis (MS). However, more than half of those living with an MS diagnosis are over 55.ObjectiveExplore the unique considerations of treating older people with MS (PwMS) using an iterative and structured Delphi-based assessment to gather expert opinions.MethodsEight MS neurologists with an interest in older PwMS developed a 2-round survey.
Survey respondents were qualified neurologists with >= 3 years' experience, personally responsible for treatment decisions, and treating >= 20 patients per month, of whom >= 10% were >= 50 years old. Consensus was defined as >= 75% agreement on questions with categorical responses or as a mean score >= 4 on questions with numerical responses.ResultsIn Survey 1, 224 neurologists responded; 180 of these completed Survey 2.
Limited consensus was reached with varying levels of agreement on several topics including identification and assessment of older patients; factors relating to treatment decisions including immunosenescence and comorbidities; considerations for high-efficacy treatments; de-escalation or discontinuation of treatment; effects of COVID-19; and unmet needs for treating this population.ConclusionThe results of this Delphi process highlight the need for targeted studies to create guidance for the care of older PwMS.
